Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in bharat biotech

Bharat Biotech's Covaxin Gets Approval For Phase 2/3 Trials On Children Aged 2 To 18

The trial will be conducted in 525 subjects at different locations, including AIIMS Patna, AIIMS Delhi and Meditrina Institute of Medical Sciences in Nagpur.

Read More

Budget Heading For Vaccination Expenditure Does Not Inhibit Centre From Using Funds: FinMin

India is facing the world's worst outbreak of COVID-19 cases with more than 3 lakh new daily cases being reported for two weeks now and the new cases reached more than 4 lakh daily over the weekend.

Read More

Bharat Biotech Commences Direct Supply Of 'Covaxin' To 14 States

The Hyderabad-based firm has started supplying its COVID-19 treatment vaccine to the states based on the allocations received by the central government.

Read More

Bharat Biotech To Produce 30 Mln Doses Of COVID Vax Next Month: CMD

The government has also approved a payment of about Rs 4,500 crore as advance to vaccine makers like Serum Institute of India (SII) and Bharat Biotech against future supplies.

Read More

India Likely To Waive Customs Duty On COVID-19 Vaccine Imports

The government presently levies 10 per cent customs or import duty plus a 16.5 per cent I-GST and social welfare surcharge on vaccines coming from overseas

Read More

Can We Afford This Wave?

People too are tired of all the restrictions, the loss of wages, loss of esteem and fatigue. More than 50% of the cases have originated in Maharashtra and its cities, defying normal logic.

Read More

India Seeks Funds From Quad Alliance To Match China's Vaccine Push: Source

Indian companies such as the Serum Institute of India (SII), Bharat Biotech, Biological E and Cadila Healthcare have the combined capacity to produce billions of doses of their own vaccines or contract-manufacture for others.

Read More

COVID-19 Vaccine Shows 81% Interim Clinical Efficacy, Says Bharat Biotech

The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research.

Read More

India’s COVID-19 Vaccine Demonstrates Interim Clinical Efficacy Of 81%

The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (COVAXIN®) group, resulting in a point estimate of vaccine efficacy of 80.6%.

Read More

Bharat Biotech confirms deal with Brazil to supply 20 million doses of Covaxin vaccine

Bharat Biotech confirms deal with Brazil to supply 20 million doses of Covaxin vaccine

Read More

AIIMS Director hails move to expand ambit of COVID-19 vaccination

AIIMS Director hails move to expand ambit of COVID-19 vaccination

Read More

Bharat Biotech, Ocugen Sign Pact For Supply Of Covaxin To US Market

With the recent progression of Covaxin use under EUA in India, the company is confident that it will be able to work with Ocugen to develop a plan to bring the vaccine to the US market

Read More

Serum Institute, Bharat Biotech welcome Rs 35,000 crore budget allocation for Covid-19 vaccination

Serum Institute, Bharat Biotech welcome Rs 35,000 crore budget allocation for Covid-19 vaccination

Read More

“Several Nations would be Receiving Vaccines from India”

In an exclusive conversation with Jyotsna Sharma of BW Businessworld, Krishna Ella, Chairman & Managing Director, Bharat Biotech International speaks about Covaxin, its efficacy and other Covid-19 vaccines being developed by them. Excerpts

Read More

With Social Awareness

A total of 2,444 cold chain points had been identified at district hospitals and community health centres for administering the vaccine to prevent infectious disease.

Read More